-----BEGIN PRIVACY-ENHANCED MESSAGE-----Proc-Type: 2001,MIC-CLEAROriginator-Name: webmaster@www.sec.govOriginator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQABMIC-Info: RSA-MD5,RSA, L/KIwzq6x2QF+gwNshFlVvoRCg7wLHKfJ3hl1bYpKnCdVvslXJZmFZGenop0nQuC XyPfflLr0eRSnFro9+ZjvQ==

0000950134-06-006736.txt : 200604060000950134-06-006736.hdr.sgml : 2006040620060405182423ACCESSION NUMBER:0000950134-06-006736CONFORMED SUBMISSION TYPE:8-KPUBLIC DOCUMENT COUNT:29CONFORMED PERIOD OF REPORT:20060405ITEM INFORMATION:Regulation FD DisclosureITEM INFORMATION:Financial Statements and ExhibitsFILED AS OF DATE:20060406DATE AS OF CHANGE:20060405

FILER:

COMPANY DATA:COMPANY CONFORMED NAME:LIFELINE THERAPEUTICS, INC.CENTRAL INDEX KEY:0000849146STANDARD INDUSTRIAL CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]IRS NUMBER:841097796STATE OF INCORPORATION:COFISCAL YEAR END:0630

FILING VALUES:FORM TYPE:8-KSEC ACT:1934 ActSEC FILE NUMBER:000-30489FILM NUMBER:06743347

BUSINESS ADDRESS:STREET 1:6400 SOUTH FIDDLERSTREET 2:SUITE 1750CITY:ENGLEWOODSTATE:COZIP:80111BUSINESS PHONE:720-488-1711

MAIL ADDRESS:STREET 1:6400 SOUTH FIDDLERSTREET 2:SUITE 1750CITY:ENGLEWOODSTATE:COZIP:80111

FORMER COMPANY:FORMER CONFORMED NAME:YAAK RIVER RESOURCES INCDATE OF NAME CHANGE:19920703

FORMER COMPANY:FORMER CONFORMED NAME:ANDRAPLEX CORPDATE OF NAME CHANGE:19920406

8-K1d34830e8vk.htmFORM 8-K

e8vk

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April5, 2006

Lifeline Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Colorado

000-30489

84-1097796

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

6400 South Fiddlers Green Circle, Suite1970, Englewood, CO 80111
(Address of principal executive offices)(Zip Code)

Registrants telephone number, including area code: (720)488-1711

6400 South Fiddlers Green Circle, Suite1750, Englewood, CO 80111
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfythe filing obligation of the registrant under any of the following provisions (see GeneralInstruction A.2. below):

o Written communications pursuant to Rule425 under the Securities Act (17 CFR230.425)

o Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12)

o Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

ITEM 7.01 RegulationFD Disclosure

On March29, 2006, the Company filed on Form 8-K a RegulationFD Disclosure. The exhibitattached contained two pages of financial information. The graphical information on those pagesdid not display correctly, making the information difficult to read.

The pages, in a different format, are attached.

It remains the Companys policy that it will not provide guidance as to future performance of theCompany or of its operating results.

ITEM 9.01. Exhibits

99.1 Presentation dated March06

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, theregistrant has duly caused this report to be signed on its behalf by the undersigned thereunto dulyauthorized.

Date: April5, 2006

LIFELINE THERAPEUTICS, INC.

By:

/s/GeraldJ. Houston

Gerald J. Houston

Chief Financial Officer

2

Exhibit

Exhibit No. Description

99.1 Presentation dated March06

EX-99.12d34830exv99w1.htmPRESENTATION

exv99w1

Exhibit99.1

Dedicated to helping people reach their health and wellness goals

through

science-based solutions to oxidative stress

science-based solutions to oxidative stressscience-based solutions to oxidative stressscience-based solutions to oxidative stress

The issues addressed in this presentation may involveforward-looking statements which are subject to a numberof risks and uncertainties. Actual results may differmaterially. Please refer to our Annual Report and to ourother SEC filings for more information about risks anduncertainties that could cause actual results to differ.

uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.uncertainties that could cause actual results to differ.

We are:

A science-based health and nutrition company

Committed to developing innovative products

based on scientific evidence

Our product:

Patent-pending Protandim(r) strengthens natural

antioxidant defenses to reduce the cell damage

known as oxidative stress

known as oxidative stress

known as oxidative stress

known as oxidative stress

known as oxidative stress

known as oxidative stress

known as oxidative stress

known as oxidative stress

known as oxidative stress

Public in October 2004, LFLT.OB

Protandim(r) shipment begins March 2005

Protandim(r) featured on ABC Primetime Live June 2005

Human clinical trial study published January 2006

Additional product expansion opportunities

Leading antioxidant research scientists

Internationally renowned scientific advisors

Experienced management team

www.protandim.com

www.lifelinetherapeutics.com

Corporate Overview

Estimated $3.6 billion underserved market

Science-based

Unique position in the health & wellness supplementmarket sector

Market moving to evidence-based

Clinically supported

Additional product expansion opportunities

The Opportunity

U. S. Market Opportunity -- 2006 estimate

Growing at 10% annually

Source: Data Monitor November 2004

No Clinical Evidence

Clinical Evidence

$3.6 Billion segment

$30 Billion Market

Oxidative stress is associated with over 200 diseases, as presentedin over a thousand peer-reviewed, published, scientific papers

Examples of areas where oxidative stress appears to play a role,based on these papers, include:

Heart disease

Diabetes

Cancer

The Problem

Oxidative stress (cell damage) occurs when oxidative balance isupset by increased production of oxidants, or by decreasedavailability of antioxidants

Humans produce three antioxidant enzymes naturally: superoxidedismutase (SOD), catalase (CAT), and glutathione peroxidase

Humans produce about 0.3 mole of superoxide (free radicals) daily

As people age, the body's natural production of SOD and CATenzymes cannot keep up with increasing levels of free radicals

The Problem

Overview of Oxidative Stress

Consumable antioxidants (e.g., vitamins C and E) neutralizeoxidants on a one-to-one relationship

One gram of vitamin C per day can neutralize about 0.01 moleof superoxide per day

An amount only 1/30th of the body's daily production

This assumes full absorption and complete reaction prior toexcretion

Yesterday's Solution

Protandim(r) - patent-pending formula

Specifically formulated to strengthen the body's natural defensesagainst oxidative stress

Delivers powerful antioxidant benefits in a whole new way

Activates two key antioxidant enzymes - SOD and CAT - the body'sown defense system against free radicals

Delivers benefits on a one-to-a-million relationship

Our Solution

The Scientific Evidence

Free Radical Biology & Medicine (Jan. 15, 2006)

TBARS are a key measure of oxidative stress

TBARS are considered "the canary in the coal mine"

After 30 days, 40% average reduction of TBARS

After 120 days, increase in average antioxidant enzyme levels

SOD +30%

CAT +54%

Protandim(r) Study Results

Causing modest induction of SOD and CAT to decrease

oxidative stress and lipid peroxidation in vivo

may be a much more effective approach

than conventional antioxidant supplements.

Protandim(r) Study Conclusions

Increases the body's natural defense against oxidative stress by morethan 30%

Eliminates age related increase in oxidative stress

Fights cellular aging from the inside out

One caplet daily produces results within 30 days

One caplet daily to maintain results

Protandim(r) is the only product that has been scientifically shown toelevate the levels of the crucial antioxidant enzymes SOD (by 30%)and CAT (by 54%) in a human clinical trial (published, peer-reviewed)

Protandim(r)

Science-based

Market moving to evidence-based

Clinically supported

Premium product

Science allows for premium pricing

Protandim(r) Positioning

Aggressively working to obtain and protect

Covers any combination of the identified botanical extracts

Covers end outcome: induction of SOD and CAT and reduction oflipid peroxides

Protandim(r) Patent-Pending

Produce clinically tested products

Protandim(r) product line expansion

New products

Based on science

Science allows premium pricing

"Partnership in Wellness" marketing campaign in development

Partnering with leading companies to spread health and wellness message

"Women's Initiative"

Clinical lab testing for TBARS

Corporate Strategy

eCommerce

Protandim(r) $49.95 retail

3-day DSO

Autoship repeat customers

Retail

GNC

Pursuing other potential partners

Chain drug stores

Health food stores

Science allows partners to charge a premium

Licensing + OEM + Partners

Domestic and international

Corporate Strategy

Distribution Model

Featured on ABC's Primetime Live June 2005

Consumer advertising

Print and eCommerce - example targets include

Wall Street Journal USA Today Prevention

Newsweek New York Times Yoga Journal

L. A. Times Delicious Living I Village

Chicago Sun Times Women's Health Alternative Medicine

Dallas Morning News Palm Beach Post Men's Fitness

Chicago Tribune Newsday Men's Health

Minneapolis Star Tribune Denver Post Advocate Houston Chronicle Seattle Times San Francisco Chronicle

Better Homes and Gardens AARP More

Ladies' Home Journal Fitness Rocky Mountain News Value Click Network

Atlanta Journal Constitution

San Diego - North County Times

Corporate Strategy

Product Promotions

Consumer advertising

Radio

National, regional

Premiere Radio Networks

Westwood One Networks

TV

Direct sales

Direct response television

Scandown supported

Co-op supported

Off-shelf display solutions

Spokesperson(s)

Co-branding promotion

Corporate Strategy

Product Promotions

Virtual company - low overhead

Most costs variable

eCommerce model provides strong cash flow

Deferred revenue model approaching $1 million

Exceptional Gross Margin

On-demand production

Financial Model

Financial Summary

June30 Fiscal Year End

Q4 FY 2005 Q1 FY 2006 Q2 FY 2006

$ % $ % % Ch $ % % Ch

Revenue:

Direct Sales 2,393.8 102.8 % 3,011.2 101.6 % 25.8 % 1,757.3 102.7 % -41.6 %

Sls Discounts (124.5 ) -5.3 % (245.3 ) -8.3 % 97.1 % (155.9 ) -9.1 % -36.4 %

Sls Return allowance (124.1 ) -5.3 % (40.0 ) -1.3 % -67.8 % (35.2 ) -2.1 % -12.0 %

Billed to customers 182.6 7.8 % 239.0 8.1 % 30.9 % 145.6 8.5 % -39.1 %

Other 0.0 % (0.2 ) 0.0 % 0.0 % -100.0 %

Net Revenue 2,327.9 100.0 % 2,964.6 100.0 % 27.4 % 1,711.8 100.0 % -42.3 %

COGS:

Direct 221.2 9.5 % 217.1 7.3 % -1.8 % 137.2 8.0 % -36.8 %

Other 162.4 7.0 % 379.5 12.8 % 133.7 % 225.8 13.2 % -40.5 %

Total 383.5 16.5 % 596.8 20.1 % 55.6 % 363.0 21.2 % -39.2 %

Gross Margin:

Direct 2,106.7 90.5 % 2,747.5 92.7 % 30.4 % 1,574.6 92.0 % -42.7 %

Other (162.4 ) -7.0 % (379.5 ) -12.8 % 133.7 % (225.8 ) -13.2 % -40.5 %

Total Gross Margin 1,944.3 83.5 % 2,368.0 79.9 % 21.8 % 1,348.8 78.8 % -43.0 %

Operating Expense:

Mktg & Cust Spt 923.8 39.7 % 1,144.5 38.6 % 23.9 % 829.9 48.5 % -27.5 %

G & A 1,125.3 48.3 % 1,065.4 35.9 % -5.3 % 1,041.2 60.8 % -2.3 %

R & D 5.1 0.2 % 0.0 % -100.0 % 0.0 %

Dprn & Amor 101.6 4.4 % 86.4 2.9 % -15.0 % 83.4 4.9 % -3.5 %

Total Operating Expense 2,155.8 92.6 % 2,296.3 77.5 % 6.5 % 1,954.5 114.2 % -14.9 %

Operating Income: (211.5 ) -9.1 % 71.8 2.4 % -133.9 % (605.7 ) -35.4 % -943.9 %

Other I & E (2,595.8 ) -111.5 % 8.5 0.3 % -100.3 % 34.8 2.0 % 307.3 %

Net Income (Loss) (2,807.3 ) -120.6 % 80.3 2.7 % -102.9 % (571.0 ) -33.4 % -810.9 %

NOTES:

Deferred Revenue 483.8 293.9 -39.3 %

CASH 3,385.2 4,762.3 4,871.9

Lifeline Therapeutics, Inc. LFLT.OB

March06 22

Balance Sheet

December 31, 2005 June 30, 2005

ASSETS

Current Assets

Cash and cash equivalents $ 4,871,904 $ 3,385,205

Accounts receivable, (net) 528,106 1,020,131

Inventory 139,689 219,644

Deposit with manufacturer 642,693 991,560

Prepaid expenses 129,437 415,806

Total current assets 6,311,829 6,032,346

Property and Equipment, net 257,717 200,944

Intangible Assets, net 5,472,020 5,578,830

Deposits 296,144 31,192

TOTAL ASSETS $ 12,337,710 $ 11,843,312

LIABILITIES AND STOCKHOLDERS EQUITY

Current Liabilities

Accounts payable $ 570,022 $ 657,528

Accrued expenses 445,510 207,672

Deferred revenue 777,750

Capital lease-current portion 1,844

Total Current Liabilities 1,795,126 865,200

Long-Term Liabilities

Capital lease-long term portion 4,176

Stockholders Equity

Common Stock, SeriesA -par value $.001, 250,000,000shares authorized, 22,117,992 issued and outstanding 22,118 22,118

Additional paid-in capital 17,282,858 17,231,832

Accumulated (deficit) (6,766,568 ) (6,275,838 )

Total stockholders equity 10,538,408 10,978,112

TOTAL LIABILITIES AND STOCKHOLDERS EQUITY $ 12,337,710 $ 11,843,312

Lifeline Therapeutics, Inc. LFLT.OB

March06 23

Joe M. McCord, Ph.D.

Co-discoverer of SOD in 1969

Honorary President of the International Society of Antioxidants

in Nutrition and Health (ISANH)

Recipient of the prestigious Elliott Cresson Medal

of the Franklin Institute

Professor of Medicine at University of Colorado at Denver and

Health Sciences Center (UCDHSC)

Director of Science, Lifeline Therapeutics

Board of Directors, Lifeline Therapeutics

Sally K. Nelson, Ph.D.

Assoc. Clinical Professor of Medicine, UCDHSC

Lead researcher on Protandim(r) study

Science Coordinator, Lifeline Therapeutics

The Scientists

Larry Gold, PhD

Founder, CEO, Chairman of the Board, and Chief Science Officer of SomaLogic, a leadingclinical proteomics company

Founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstarmerged with Gilead Sciences, Inc.

Founded Synergen, Inc., a biotechnology company acquired by Amgen, Inc.

Professor, University of Colorado (CU) since 1970, where he served as Chairman ofMolecular, Cellular and Developmental Biology Department from 1988 to 1992

Awarded the CU Distinguished Lectureship Award, the National Institutes of Health MeritAward, the Career development Award, and the Chiron Prize for Biotechnology

Sean O'Connell, PhD

Chief Medical Officer for Cascade Medical Enterprises, LLC.

Assistant Professor, Department of Surgery, Division of Vascular Surgery at EnglewoodHospital and Medical Center, a Mount Sinai School of Medicine Affiliated Hospital inEnglewood, New Jersey

Medical Marketing Director for Novartis Pharmaceuticals Corporation, East Hanover, NewJersey

Medical Director for Sandoz Pharmaceuticals

The Scientific Advisory Board

Stephen K. Onody, CEO

28 years of experience in healthcare companies

Chairman and CEO, Colorado MEDTech, Inc.

(NASDAQ: CMED)

Vital Signs, Microphage, Boston Scientific

Recipient of entrepreneurial and leadership awards

Gerald J. Houston, CFO

Founder and CFO, OpVista, Inc.

ROLM, IBM, Measurex, KPMG Strategic Services

The Management

Javier Baz, Chairman Private Investor, former investment banker

Dr. James Crapo Former Chairman of Medicine,

National Jewish Medical and Research Center

James J. Krejci Exec. Director, Epilepsy Foundation of Colorado

Bill Lister Ret. Senior VP and General Manager

Patient Care, Roche Diagnostics Corporation

Dr. Joe McCord Director of Science, Lifeline

Steven K. Onody CEO, Lifeline

H. Leigh Severance President, Severance Capital Management

John B. Van Heuvelen Ret. President and COO, Morgan Stanley

Trust Company

The Board of Directors

The Future

Grow Protandim(r):

eCommerce + Retail

Licensing + OEM

International Distribution

"Partnership in Wellness"

Additional Products:

Science-based

GRAPHIC3d34830d34830z0001.gifGRAPHIC

begin 644 d34830d34830z0001.gifM1TE&.#=AT`(!X2IXP\`O_>FQJUO0]%9))?ISYTH$$'-J0B+@#MHYU]U/@_5C7N?M-M[G(+_-P`70>[Q2F0=;%CG>8RET#$I)$XR8`MY8A:"","7!``C0`3E#(``@H_T."#*Q)MC'JF\YT'_=P?*2#PJ,*YW16OF`(C(M2>8/^V?VT5(7DOM&='#8G1FH93LG(27KN,I^6R&6G!G.W8?:F#S'\%U,;#9.,*USI6?'#ZD6?EHM5CKVV;G`/J_B["AIX4X;H08D*Y\G#5RP,ERY!=?M/8>=\4GSF:)YK*MY/_VXM*^WIL?!*T[D@1('NG"7_4;Q?G?CMPL7K'Q_>:X$3\L[\#F#9H0OIXIZUQ\'E8[,_//V)H]V@O=9XVY&;Z#TK>\-KMU7;7&_I\D90$[``E`P%J[!'R-(!K^)TZR)Q6HL2U!L6`:N$LZIU6BME3+/T&U>AT?8U3_E55CX4T$+%(,`)(,55`(:4/\".KB#):`=/=B#)@"$V5$"M,!"$/J@=1VB$/\B#^*.#-GA7-!A!,.B";>16'5\5SA^>B9/D#1PUM9CM?C5)Z,5]*U9DH?1">L(:5O,:V&$#3#001D)@`@5%EKU)@B)&3?(F7AH9`1=@&;.XC$9HK8;EDT9J8QKD.>BF-5X2*Z]A`B^W#1%9J(1`MHZTU"+U9%HI05)-)")7R%7"QH8$:%.W*>#5ZJB?#MYL"&)4B"4JRIR&(M&>YM"$6U_PCYL;>^X`-2*WUD1+6L&[B45SY/9+10RPANJ;)Z`Q1RR@AN)H"6(@E=M9A:=4KQ`(:."`!S3X570@?V1Y*O3N'8",$QZ4`^7!3=^@@$4^%FOD@5EFKG56+1:Z9(HXP(9UH0&YPU04>-WGM]6",,LYTMQ$W':?1*"3XPMXE5S\T(9)#]=79)5\EH9V%4895`UD9DS;):!FGA,I\P(`WCM408Q^)"D,OG])F288DH#1`\:0%``,191D%X))MSG23P8CDEGG#J7M?*+0[-QP""[Q4:X?*XD4XZJOYG(+8,*;C8,OLP\GA(`\,+K@\B&(K2P:%68@RJXJ)#UPUM.4T%:B.TN10:_1>,N53`!%L")'8$$P,37`EC[L'%*H36K*M]8HK=LZ0I$S=Z6"^2Q*SXJ,LFC]'A*J?@`!]_0121]04(`M*K($G/I@/;12CP\&L;=HQM4(-JQ4K9]#[J11*-!4#FQD`GRI%RX@D"*/0P)T.B=7EE7HYV0TR,1AR3-V^R&TKB12*H&KS66+F*I,3/T*!Q*\_#,5WM32-MQHMF&W`M1S1R(T8.UR,1GM1^MD)N2Y=+M)$Z2RV12>XTF>ZY`/6EF>Z1F=Z*F>[6F=VNF>\2F?\TF?M]NTQ?N?HK"M&U"LJNJOB^NM=FJD^P`$SINXB&H!V)N]M3GNVNHJKGJH4F!NHQFJO;VL!;.NW:%JW6PJRGR`$,L`!^2JI44NX?B&X`=NAMV:J[A"K!84NH;/NR)4NF4,T00_W*VKVLSDNII$FZ?0&^6(VF`Y[#=_T7TM3-)U7^U'M2IJ5LO0/V?@TW?8/->*^OZ'-(K^[7%FNRKG*96C.%H"L)#D/%^*P/WGK@L#_%'&^GDM$8WJ9/#>H`E:8$W[^3G-3$?+/R.SL1!6-?+:[RM[BDLD+@7T")!?`']JKCG'JT7OJQTZKRH+`)\#@HO?]@L;PV6[]#@$`R&7YW@7F6\\394;BJ[K"F2@^KD022,;BHE.PHIZN5BZ@KB/>Y[?MY+-.PK$OB[OW![H7N&&QN3LNFZ%8V[*B5ZN16YXUM[J.=H'8ZK64RY^362D#M8D[PZ*YF-KXVNK7'RPK@=*E>68>I0!$5LZ_5BVL&*[RS5KM^EZ-J(;X-P[9`MZZ8.UZ=FFY/MJT&%VJ8;^I4,1[>/HC"B>YG@.L"?!TYG,$?O'M!)L$'M6[@F]@_NG/\MW>"RPM\LXG>6L&:A-Z%N)M[XBU8FO*4NO!E[B^KIRJ`^QP3GL*3MNI%X>NQ[QKZ[NNJOJPYQG.5GNH;LI]MP'MQ[CK.]V/%6INI^[F>^NK_O9;`#>6LEV=5YYQAF?G7R5&J08,36,:S.,&]9-JH9UA](5]O+2CS$P09TJ8(_G-=+D#@Q#I6PM.XWK7;%_1XMD,0W+10`9IK&.=PRTC>-?5KBZI\2:XRUZ;TK;.)Q$\#6#?M+D\I$,G@**1CDZ!41@8UK`LGLT$@\>4KPRM@]CYU,F]IXU-3I?CNKTE_VUHBWUKC7/;V#R.'$Q3G,)"JKAN0ICN/PHN;00#MN1O$-F(AM\MD`RUXXHR,]SV0^^?=_MK2^"J"$4C.X;XY5>"3_M]>8;&C33ALD-C622BPL5I1X&J,/\K(-W-L;5+&X6_0K+02E=A%M'J:T:?7UW3(&GPCNL:;1_D`UP^*G!/5M=ZL\J5HZ>O$=9Z^\(2GS)4>5-J;SM?&9[W/%S8*[I'-XXZ#VQ:-8KF_'^F:J3$#,.Q24=]S*)ZR=V,X*AE503$"()RWM5W!H(!"7=9ZE:GPX6+W86^A'BX?&"QC$8,_0>3WX8S21B]YG3YQF+/&89DAE(,`&@Z!V_TZ"R(MJ)B9M>&X/])!;Z!7.AF($&'T5F70CMN7"\]T'GUXHI%U*Q$&SGF)2!MF''QXZM!T(.4T=>DGLAA&9'_:M,V#7E6'PMG,8AW40V&Q2=VM"0&D'^6,#='8(1XDFP7$!]'FW&(7,AVM".(FVM9FF\M'QA"6ATN9^)%SB(,@A6PCMMH.Z1WF[^#^=>);:=Y`XQQXTH38V!0*J;QZAE03H*;_J9'Y:;UBD7:8H$8UW/5$FM8**9@089I"\97KB7#`>*C!=Y8O)IA]@TA55S,NH3+3?SFI7X[@M&>D`-+8A7>"9>02B9H1F(/&W,(`I2E`71YI(,.:"-!+VH_U@$++2%`M?)0B0L0(C+>,D$*DC#@@VPKMX[BAXY^#8R\OR@TA\[5U-*Y)ETJN!F`CQ(^O]U(5ZESM*58B)X(0@5^_(5_]M=9T,A7]WB$3%XFMMY6*Q]H5TFSH@EK%5JU.%LK=:HA18!"@!XQ?2.;@)$2:3MPCZ2JT$I$?^NBVNU=O%&>G$PVK0HU3*FSD.OLBN]Z"`K&'$6=EM'9N(W!S,IM@@M`2E18EY"7^MHI^6$AE((V7)&U!A,AC+08@`$Y;GL:('*G-W:W"BOM0H08(@I6`4PI!72TZ42L";A58C9OJ`:1-BM%"G%C*8=,HW9ZM^M5-.MA_S/)117I[Q_.EW5=N+GN$'O%[!\.E1(05@@/>RR"`$,5B[RM!GUL(2,@);&O;!OEB\YW:EI,\17-GSM^LLW$ZC8XJW_R1'ZXB"-4Q`7\SP=3+C/Q=NKDX%A=-:J-L[:-6*UGS7/W\U!L>F%#B;MN+"Q9MR9?TFI`98=Y:P&]N;?3G@$VTLI$+CL''%E!T_R)X[QMD0?_&YT_&3/8>))2A:`\\I,;[^N^;>1%+8QK"?/IX_X%7,!0#P%OAG6RR`4O[I02[LD,*OWE9/ER),*MBM)OW8.;11$]T+(;'Q(%*ZO`DKD.'B#H"9"O`#JS-3H0M+!K>2KK>!\^5F*;5L?=5P^IEY-M_D+E=6`]YF`2/EYT)>8[BM_*C%V8G=/K1*+Y>+Q%=RG0UF4Q=SNQ605EG5Z,G5A:)>FO%34T-FC"MY=AV!D`5.__B1\[H%:[FZ%5=#NWF,#3BAV[C+99#4U;HB,5IW_UI"559$'9GME%0Z`P;:^QU6`69A:TYFH\9HJ:JKK*VNK["QLK.TM;:WMN+FZN[R]OK_`P/($.*'$FRI,F3*%.J7,FRIJR>5J!F+I(H)OAHIF@UXNF&%R?O*&MJI84.XC_'W*3VX&IBGE!676;#-L![@&7^.::.SZ"XXU#GKCHE#LN0G2'Y:BQ=%!IHYF@QFB4H)RED(I2MP,DHV5#%KKX`GZK,`RXV=)P\C36\F0DGCG84PZ(XP8'-T$@#^1^,M^*:R&$*H&;U1WC"B:AF3)6NL;:#\'V@F!M5@(YNV&SD@W%$9MJ2&!I=R).3F-!%EMK7ET3V4?+Z69B\P:F$$''^"%2&54UMNR-I$/KO2()1-09T$G&0P5E@A:P^'MR$8Q&8$Z9=G_TBTF;0VR9MH&,/I:F6STM:O7X?D=@@S&'AJ&YC]H3VMA;6H&;_YRBD],E!7=^\0]Y->)#,_O#?;KWM-HW$H((PW(7!W*Y=SKH/*ZIG;36:@G#VTF(%VK7%>J"+Q3'+QU,I1UB!`D87_FX4U"5V:YIVS7-GAV(8=FL7(\`K4S1D+9%R46R!]N,R@9NRK7!M"8]R13'QC94E5*U@+3C$V]9*AI^D3V9J6)]V3FS2%+3L'FM%6#'T;&GH[-7YMC0K]'#Z!96"1V7Q5K85(W6B&FR96AC-=G'?J//*9?G\*'2E!'7*."$YEKR/IM7,.-'.&`??&$#>-1EY6(5E,5G]6D,9]?Z/3,!EJCK$7X7D'460!_D/ND825I6%:M^45,D[$7-2SF.=#9&$(R>J6%D22FJ:UMHOL)^5,N+L8I0?.";V8+2KY,@="FT\\UM2)JB,;1`=%1NWXQ`;59`G?W]SP5C,YT,DYJ5PW#=H&;K1L1`#=Q3(2\M-/M>=7C%B%"[3D2GG4CIBZ5JTFW="6:`?PY>,;BZ,;5U%)N@R%C./F49'5VOMZEMP$PX0['@[XDV7NPV3NQR/-B3NEL+GC=B4YHI$)V_8M2YO37'S&>79H%PUM-YJ%CGEA)5G)32[GR"$6+7R;^Q)*RM&QXD+"0]*9NQHCA)(\0QL,(Y,2\AH[M9$)TY%&T`O4D-"Q$+#HRDOOWZJQ#'!!4/CM'^M,.TO9&+R8QU]X)SPC-FBN$^/'O,*,C!)TMTF/E6BE&@:!R%[%2-`J,IV3B^'M5'0((!O!HPYEXA)3D#MM*>Y2XHCRHH]=^.A1(]%&XHNO#Y>S#L_E8!/GOT/IM6)4.48@*%()DM[70ST:-"V/*9>)@M';-I$;R&1#]*R6D]A.IAU_B`"/2HMQ2WE`$J&P.60T!QE;ZBC8N74$KUU,>$5>'G?3V`FC#N5RQ_L89OU\*"CM%B'M)HE(Q7O,8@K&20U/-2DA`RNG510Y):5HB8'"VQ(W@*DH))P%+-`B3=?0U2N`%(93M=KA22RBV-\Y!YB7B-(=/GB"27YPP03J;A?BJ4ZC6K,RT5Y.(E$#S.;1YO&[F2PJZ(QM!5M1(2B3%K3'O9'#VD4M4((2C`&X5^[XE(KV":J!M4:]U@!9=2VLB#UM8EDX+6V-2?$Z8C@7AQG![4B#?5C4JVF4R#WA>VAK%\3AJ5.3F:M:4RS(%)'J)S;5>A098!APD-43AFJNYZX"G..76$AX)1![!42:OLG!Y$1FQXAM'Q\7FI_T3%9-]9`R_L`4H!'\VGR;F_'Y[=IB"46(-3N!$Z>*ST]XB605_)L4MTO_=+1+5;N[37T8VL"ZA8FC'./EF&BI9^BR4&(VBHDB-"M2*FB,GPT8T?L`37M6ODZ:%H?6CTCR%K+7P$,M`-1.RW8_U3,EMBCP`!JA(KKFE*+G2.J#9H!#!%=MNQ(Z,UV\6&MIOO.C%M:S%!\RN[`($7&)UYFRSC+)U_K`B2")5VG%EI$3ET41M(N$93YFZ`H'+*#IL(A?=)H>H0IKR.S.B*>E(AI^U*=JM.*@QVXYI/+Q!L,QR*3*Y`:SB#\?0R+4QF7RINN11@D:2!37"'*`IR[`]C0M9MDEY[--T11FI(4@193&8=3$;@-E&BE/*Z6=30G$DZ(?1$U[0T5ZVB1*REQ>-(M3#-1$B4R.?]T4K'8W-5I]=9)(="6M7,M^T)1>3`^/7!+]LE=4SV``R74\S%`EU_52B=PBI8%6!$\$UWY-&R1YVX^X7FEN/S4[PT%[?+M-%B=HSK;47Q@5&R#7V5(=DF&=%%X178XCE([3D>29CMM1E1"56*23.6I:ATA]F:YD=&A6=F"'-G"B.J=E3D^YKE92MUY4MG8SU63877CFL>P536*Q!/AJ2FQ0T2&YK[M+:>1E49(G5H^>A:,SA_!PY"J[$CSHK3AJ`XLM#ZHC1+@.@5=).`^)4Z)RC;%I%,C687"K$O,-Z.J(YL):W@"D=5\ES+F.KY=)MX"1]B'Y[1EX55)K70%B'T9EB9`?0(0&U590-QJ'-J1WA3&L$.*KLR$)8[$H?M)!ZRE2SY5*U!%?)7F,3HG.H0:(B?D,@_:D0%M5LF,&:^$B*SX]K"GM6%(H9BC65`&BI_5;5P0D5E18D*1D@0*4W"8V]MJXQQ1MU"(BBU%4>?91MH"YPHY\$)PV-O]VN\5UKRKB745[Q$$WTQUUVE)RLM9-$?T7S"XCQA$D9J8F;-Y$(G*`9"8*6M@A7YQC"6U";C./!%#DS'BQCQN1H.M274#929%YD:=$#W!12H!FDJB],%)FKPUY$).9++'^VS%'0%:+U0:14U)MG=>77USM81C4"V(,$@])Y*Z4,;.0%U#5OQW.A1.>B>4VGM8(_HG0/5&J$@++M\S^D7...WULCW!?31_Q@6'J:F%((LMXQY+1!!L$5U%8^?D%^OXKDYH8O*LF\3L7KK08EWI7.5FZABXFL2"5>=H[8$UU8O'T=RI5XVOO9AA*S.6]P:S,RMBT%RZ,3]7'(/3K3Y4&*RP]V`PUYWR/]YC(+MLYI!W'#6=\*S[671>31[M[^XS$Q\16?P=L8WG`+;S-B0+Z)P%^0PV;$0[*%\F:5MLOO:)!Z5CW@PI,JM;^O2%)S:7PGG%`$FU^P2QH,98-?7=/FB?_GU*T-\*8`0DURG((B*_MH+-4/QMMZ$TJ^L@E]/%:V033'=HP//"")2[;7M.1&-@MB4N2)6]@IDAXQX+RTI,XEG#3X8:\)VY]=SSUV&/YZ("25V(EIIZT5X_ZZ`8UMJD@&]Q0(QDC]*%[#4FZK-Y`^J?M\1DXZ;F>,^"JX`EZY2F41N>"M&>!,_2FB.&@3@2&Q"6,BME2S#EDZOE[F97#D[,M,\;R@N;B8K7'J@H)>%"0$6F;,XQO9MM9>"&C8!8%[IJG+&$%PJF"VF9*.IBQ]=?E9"7Z!_8:N/K041U%9);`M41ED[8DG`PF&NC7M2_:5NZ;2-+Z;(#IA/WC_"AGX]`PM.VD/Q%GPQ:$FL1ZNB"6RTHIJ0'^`*3:0M,BI5"R+;040*RA#FI:!".U"WZL3)C$9W8`;")48[:Q(;ZUJ\?FF8=MM49*)`.MJD?G^9U$ZC\BYYIX%V1[>:R5!\`-.J9Z-Y$!)?\M9@X);&+`^*+;R&PF=P_$6)#8%I':IKM3N(UFUU!J>&FJ\%P_EW*!!@(W*DXPM!E8>O2)K0643,@RNU#DN(C8AV6@QJM0UMTQF=E"=^57(STH/T1.MU'?__JB]+095W8I#@-55W^#%+_!6I\1ST;SZME_IL(0X[W]@%G_.HW^VO[VK4`23JX#_$#-E1A"T;#>REAM-K-$116:#[2;&'M6J#B;C38M]L)MM^/6BXR[O[^NNDN"F^$,V[M"],88Z0J!G$G+]JL,Z4^^LY@8@8FH.##*2/SJ6M'3^!)40S`"EOK)7"DR>E"MC%CLZ)=!T+RP%TC8R^T15]"4`S=6ROKD.3`^$F'31TZLVD@+TNRNF*2J\MV/Y4"*^AMXS,J*&TO5X>\?HD_99C15T03)HV.,G;$*:J=8J0:CEP.B-K&_,LT7`CZY@HQF,B:J,QAE$.VG>92Q!\XYF7,:IQ,J"7M(6JA*L"EJA+.I`P1=\L!.8)J%6'72>2/HXY$0;[KD.ZSADF8B+M21[H'D\A+J)5D@';WD98M\PX"[)G+59@MB=EE`;:RAY+"U>`ZZW[_*4[4'LNZ^[:)TX48G783`HA+&8(9;=QKK?N71R/FMS[@96:\S%1'0B.2)V+IE(`0E6+@?YDE*=V66RX;_!^EI?/,=?FW@JK/]DZ'@M]LE+E,H/33VUE5Z8G#QB*?B4J#G7^3@33T8WB3S:P`"WR'D=26^:\3U4(]$DM#_W+\B!Z]"`15V';0#Q'S`.ET@OIWLEX[[N!S0B2V-FXI?`KCWTM"0!SJJ9H0NO\;YQHR_)."#Z,[A'PP!2@2J;05EF(2`"Q!UZ!/MN*_G&M;,!`1AFJ@@N)+OZ4@W4$8HOD1Y%V;,Q(BI9XHY84!YODS,P*YO]([PMS+]=FMR?]J,JM#5N\K_,/6XB>SZ("7]$RPZHC('$,BKL^@/,3KX`X'3B$ZH`/$/&0,M#P04E*J'/@(+E@SO5,?E&`=]L"@K'N$S#N>VB,1IR`_,_*9K4'%_0%!V:B6>M@"P(E>04'2'2L##M3*694I%M#J^"$+`(NP4!QP(:]&G>S%#!C*ZIY.V:ZJ^SM3C!S%LC,.(7R;G!$Z`_M/JEMB*AB0BBHT-`+"\'E]D$?X*:&JM"&+LD>;/`JM6N$@LDV,H&VV[">JZ&*VW`&;IJ\'"R$9*4);`B+>TFN+,FBO>UI"'0/,Y%-WB+#+").X!#@KKB7'(Q1B2DABJ'XY92'.Q!ME"!J(D/")G(C3]+G^$0#`-4+^\X,?4P/]1R.?$QA>-HI1SJQ:>RJ:P(#GU9#M:U`F+S+GQOH$3`X/#:D&\5JP18J1]\9C>'[N"+2F;4:L%V@)-*3*8^3J,42NM(XTFXQ1R,FO+K&@@)L3A^M2Z."NZ9.^$]*6[WXVQ:O`K7DRIEHXMLB_0[_^?,DN-1I`ZX86TFHKLQS_F(W-J8>AK-&RVP21\K&*M#*1$$*M\&N9`L,;JB=8]],.'8K51$=3M]`V/>F98L(&)A$,B2V(56]G6M1XKF9(W0+Z(D$GN[E0Y*/PVDECW]W]_R)_TR;,4QPIKS$\D#+#D:DF,M\PL%1UJ8,_^MF.X]SJYKU&AT\I0F`I`CP9`3E9`4FJW)NJ!/[_`$WP]"JW'WMVBJJ-+2?'B\44M#YGE*=RN)119%*OTUH:L2*4'6,GS47>./@&.D=TU4)?78]MR+:C5((F$E5*4>9F'EA1+VD--Y4+TS+'G0M'T%M2^DR\\$."W6;GM;,0:#W6]4M((+)Y5`!_Z@7':\/][/W0>VCM%^/JU:YZ91)7+4=$>U-7@L/N78\S8C-+U?=E);M@;#N+^A&M\-3M&%>JS&7P"N;K_\(AK0M>G.>Q2O"'$^?8HM^;]H];6M]\^;?K=BJ-W.P-$US!A+MMKR0_6.W/HF;@TS24'')@PT.T:408M%]8X:HJ((Y7E6["ZA@#EQM+=(4Y:^K6"QO]:JWR$[53@)+5N0O132J):O+"JU/BUYC&(,O$-%S**BVZ5E?3@Q^)MZR#*77(UM:O%;H\IB"L>`[0*Y$PV_PVA-/I\-`%M5C%\"K5MNK2U96W-RTE9?I!:^QL"77Y&!"P^RYFK]GCPFNF4'!Y>1PXSF*!7_M6:M7MYY@#CM-CZ/@@W[2=?(5CW;\7NT"NA5+S]2YT#-*SO:^%9R@C.9[/,PWMU_\555&?322"!$%.:L/KFV=E(G']P?553EVG9QW/W+99:0LK!,\2`>A'EV58MQKP7(E-KWW6>"1Q%P>36%;?@YA^_4H]_=Y"W#E5^>J?0J8>8:TU40J\=L,\HFZ.\'"GH>LJO8B[.M:JM.^9\/K#YM6ZYGNT^6W"CRZK3X*!EVJ,4?R[>>`T:(.4O_6$/(B>A,:4.O$8M(K&A/?@8>BA*4'&VP;#3M&*F8(,&&L2PPE$&7-R42:-#SE*XP0L-PLM/MF(1&KSLS@X@E]+M$8HGC28-^MUFL)+HM**W(%#SO;79I(CCLRIYDB4W;#=VTQ6?W&@M)5("NCC6['R)'?D#X?@+=QF%('*>6T/F$-'],[5'R$1';8@7*;BU9,/5$$3C)L8_"[5WM`ILB^8S3>0H?82/QM;+FCKN?3D\%2J#;2`PD4D-]189,K&R\V;O76UCMV8^^[""C2&HKT9L,C):9L-HK-J4'%B9`AMM8%.>MP,5FK,"FP2'^YQX;!GE`S_O,`2>.*I>)3M%-QHWW]P6:+C8?A=UPVXM1UOB2,$`=M"KA4!,E>B8U@;HA0&0XE4-4#XG:6U%1SYO!YU#PRM8P?0F+JC@XM4!.IV33EFIHYM_V!7^HV6_/`2FSTHV"VY7LAFG=U-@>UC-D'CKI";:UUH,T,M']\YC,W4A,]$+C-C"W^L>3(E#7ZW8B%ZCVT^S_AR[X]SC\FLT1>\AH;I3JCL,B?65%Q(AWU\I5T969W6:?9NVM1FV'Q,O,,I3YMTD#V#+WVLUA]PM;K6@?7O[LMK08$NQUOR#/N;CDB3[G,W8A0Y9"ZMY$&I6.:UB6P>C=>P&&PE%\-0L#!N3ZD61]C["S(N?I*!D+;,"V:R;F$!Q+K",WA/IP0E=ZFY"J:Z!1K>_MGH,/IYU2"TP+.!)DPIBHMEOIET40\XHVO=+S;,-T/F,$*;2&*Z^M1@)9J,.$M*MS.M&U"@VNO[1!9Y:H@E^Q)/U8X(NR9872[#QUV4D*NHR6[#!"FSO_28VX+MB_QZBS^V`O120V2$S+$Z^D1S)\(RH$F'R$Q>NS.Z").,)L/C3#SSE._"Y8^M\B??R#R+$.H>ZR_>ZU&1V2O_W3&59QM`=%2?3?13.Q6?@\9V7ASB-7/@-L5HM;!J_UR5?J#Z_",:F-TNB"F_7R6Q&XR@UKI$,>+MZ*6XP'DQ""IR"_XA0:0A-"!B(L(?#D9=00Q!8F9!-HM\`'[I1,(4NU*`#]Z#U0VM$`Q*CSTNP][>@@8?(G;@+!E#HA"QC13G+C->0A.O+1#\\N;_4B\/'NXD8B*\O^U#);D_Q:+`0.`LH?,(/$X(VS]+/3D$@M7X\3MHKV(-,0>P)4;J_SQD+D5M/F3B[A$/`WA7&[_*N?5.AEKH^-'BJ6M0DPN1:DLD^>`MK)40*R/BQC*(@])64[U\D(G(!?A"X_8V1S"FNP*JP!M$4;*]FD_(L)"2N0CN4,2-C#E!K#);+,B4M,TGRP$.0,'P:XB!H3,!/$FK4('M5P".Q=5A?#;1V3;E6LI:N$G^BP60&)F"8925V+'76JH5X'K.D0`6-#BVK24H).;-WFD52%AUYWY:M4=#ZJ+=&YLHS!?U';&2NE0?:4^W45LUHF*2#96]1:=SO'"MDF&4:+=VV)4)#99DAY*@4$A5>N5?G!,LN5>;=(Q@WG5E*=8+LT58G8Y5UHNUMWG79JNAKC.F,JHEA*W9)DHB\[B5!++&CD*@O7L.,4E8I98.HG4ZCM&WH3>G1.L;P%@N]F38%%Z&4=:M0VP5%XDE^`A(-9:4#I"IJJ32"%V+E8?-F)0*NG>N!9GX5[?(RDVX25BDQ55!M983"$9`;J#VUP2RK#TZE4G0LF'G3R'.AYWW=)=*E^EY]MM9CX_YV&YR&^Y4BZ3H0ER[3#PJ4G:4:+JE+K"-5]Y357U.:N\&5?U28?:D%&9MSAQ(57@?>:P_Q[4N56[:-V7W5ZB2MYTO]Y7725XK67&MR/F1M-A-QA:0,J>@6I?*(@8N*4B6NO;"9N9B11[E9TW59K[%I(Z-5H0%-M-DRGE?O!/R>0O@A>#P/%4).=V;*8@8L).*OJ)L==-^9[1KQ:XT2IJJA!X*'2[4VMJ14SOUT>C:SE=K/3MC2^7K_E62Q63;42L4H_$]^2']J9H)M28%SBC9"6XUM;MDIO5%67C6LZB&-A;(]ZA6-YHF%T1X5&B8`[>7V>6_^)0V2J1YMU?Y6B=J)/GMDL[-6UG=%!A/`W*#&'!5FEW#C3*1LO1QGO).@U2#K;1V;HZVYG%@E-+WVO?WMN1&T]=1Z?'NJ-GO\IB^BZ5TL6)[S%E@\F-4:DB@2IBPZB`WZ8TY8'H-S\F2AM3*'-6@`7DQ,48JDF4\!ED5(25*Y-("DH,>9"D0UG!YL2:Z4D1(I$-5X6:MN$18I%V[-%8,EO(@'#XX'C$-F1"A(Z-/*!;A86,JPF*GJCZ:F4:4I%A;';I4MP_'E$R>VYO"KA'`2JU)6XE[4RK#873I/8@J]TK'KM8=N9(9)LU2]53V+7T\+$6(.12ADEQY=WA$JYXFII''5=5UIY5'89LH)BXV_4RQQ:O>M6BQ>&5NG=,!8:YQ1W">"-?7\0A43/?IF6F3Z!%U3[Q?+7?*3:M]^5A)YZ)WDKGWJ%W7M6@@3][+"K(L"0.$"S%/"4*,F?/=%L)EH#(63DX%H"Z@BII5SSN:50SBWWW!GBI:M!8T]2HZ%$ZJT3@7JS_\I#Y2QI`YR(_C%2"C:H@V!4L99A:HAI?A('R35%NS)MW0X*D,D-C.,YY3Q!4`(G'\IBY=K5M2'>-_G,@MNA6'5@LF=':VO_>8(Q?/0QG]UN'Z-NO_%%M)GNCB=5&@Y-W+)WM.>]\:/8:'-!AYNE9"9[O4>.XL!!'>%HEJN^>3MN^W@[SMR/?\[1QO'-O.+MVPR2U$%YN1Q*6TY"DM'N]Z@WQM>B8SOHN^9D('NZPAKW@!SDJ`'#J9)%MDJJQAJE[^1M]]B'F^:$S-FC[&>@)(6:.[ANJXJ8_+6Q0\J1QFJOFY.>N$FRXM,NQE.B`_B3E`&XC('1A@&X>(;2ELD2(*U)(,'3J@2CM3&(A&(.&]8P>2"T/S(;%Y`:6!&WHZ.P0S$9[=`&'14J:.&TP*S/M'.W;ZHW;MD,1A"W;QA$4U`O_@Z#(UGIMC?0!X$HME+P+>\%9Z7A%WJX+`4SS,TNANJFQ[^JUR-,MB_T*1V8$R_3B*@S)AX4;0&=772W9(,$7@T/Z7M(!#PT@M\RO7M@L\!UDR!XS6_IJ4;.-T\`U.4N&MAHDOPR53O@B./#\VT+7+:M=Q@F"M+S,,OVR-/:>1H11-+#.H$7@&-W.MY4!OBD$O&M">NXN2.Z%%SW9:!Y&DV,Z08X(X,0RQ_L&4\ZH4-"F_F%VM3,PY\J1XL1MIL-V^CSOBNEQ[UT8R6Q]/F?V[-I],*,;#H&X'+1[]@U.!YI&4VB`]M:3$:BF%MM,EGK3&Q6H$%,?&3$FK@\N$\`.+4RQ3XL+.26$=$A9$9N.A$&';D]1.9*@UZMHZ,^YYBHG45:H?77-+Q%=J,K2HZQ3X`VL:A?/E%YZ-M!_RFB%\=\_V$F&WJ(MS**6$NNT2HH%`=D?+'\L1$=TX#`;XGISAV+434$+R1(X1(E9">3O.094UF*KN%@.ZO(R,J6PSU**7SU7>87/-2`N8HU]QVHGS3-M+`A0+"0N,Q)"`X4W68FO#"@C,U6F,E!U`EK49:)T"7FK37`!Z:27=4Y%T#1LMX,;?P!UR.IBIUBW6!@5>*-UF?SMZ*D84N@D20GZX]@2B%2AY4$:P\MZ!5LEL1QH^=X/`:7FYZ/7:06*8%:N>Z'IC`[32]LXMLKPQ)6"%B8!"W60-026G*#I[61:?!R&MELMUS$HG:Z2-=Q(P#2)0RU4SH10N,('=?DE13;K;V1T&R3SN*PW^;*7/[/?#IH]N]_,B-KJ'ABD.9E`*78UICF!,HYD!46]0%Y!`")HDMRN4\@O$%";%GI$IE2J"@5M-G4ZIUA\N62U:2?60S7#5Q#GMMIKM#SG=3LX0*ONK%(;41I>N30,"LD3#FL[E3\JP]H&GJ*--5JMIH'568W8>4H">6*:+73H_L(&V#ADRZ=G71_Z.K*H:M$2RROTDDDFL5DI59BF"@R&2A0C*[.$8)2Q'FL&IX`UJ9(F]Y([M3W,)Z',3H;JR8-R/,`L47;0D=#*K2[LK3^NS%^D)H8@40W$Q]@*7H\HTI?JQMH\L9:[&N%]DN]HF?\Z`[)KE:U3AZ83M-B@D(8E@Z`(OP8)@-`I,M@SV!8J;!6X*NB"#NY*8+GJZ@6O#HW&0J0^+-MM/+NM(11L*DP#?:&\/].#G(XEN,NB4CJOPYX!D3`/H3%$>HJ8()6.Z*`4MJJL+^RM>\#\M,\?@VS$Q8;TP5!PJ`R=43#ZS_!27R2&>V(A'$B/>(\#ALZ:PMB"''M#"2(1-_,+>H7)N@@8+5"`:P$K)1`)D1A8YC0;!T7+W_+&`/6]I"4ZFMMQQR\=&N%D_#$ULRJ"CTX,S1(::L61`PF9G*]:N*WI9D\8H(4]9&>B@*AKK(]MIJ!+.3FSZFL5,CW"1AK!/7O"F=')_#&;I;1`_@JM99I+&IN544!`8")*KC"FM:R/2*_N9/%NV9@,Y5\N;G8&@$S49V@-`:&.D6XPP2W,_JY0A*6"/8V(FPWO#M)\DK_M.V$%499ME!"'',MQ(61WW3=ONK*!4'!JJ6)LS"UR..FS!47FA-`F2[3X1526#GZ0T9VC+^OM.IXI;4>[ZRA;BB2*TSUWG!57X%P[H1;PH=^>2*2'H3M0NS,D:31+RP>"948%M^:G9;)SK[)JM!#;6N2D[!0RA@S9U!#!HK9ON@DN=E6F"6.:HM+VVRREB+SZ]:E("DP1I'S-M0'"572FXM5$XI8%;,6$]+5RCYS;_AT")\*"7AJF1".R(1O&I5&N$DW!SVEQ4T,Y:B'Z>UM$)U+VY,^&H-+"?]7X,_D6DUT>@E&_=NHO$G11%W]0];!BH[U#">-Z%IUEC76MP-8_4T)=61T\:CQ[24I.\`2N8`3.^**HA)Y_,=Q)+`2BMA&[:R5D"!S."!FLMQHMH,EC1`#:#O8))X`2O6)/U/J(*$6J=-HV;;J@BJ1J#K>D&$-R"R.^^_(U@M21C?'MWI(PL38,M/U+T9=D*VO:P*?W)P@*5(M.46!HYULF)M;2G%#1V^]^Z_!XF,O-#L;*T6#R!.MS&Q2.U92AR13^(8PBA%1+B/>9=5P90-D&,&^'*D["S,:4$WRQJ8SRF@=:K#%NF155LPS?.8C.$RMD*1?5D.;CDSHG`]FIN6M2[H!_2`24`(2:0QH)F$R-@8ZK@U.NN,]U@*RV"L:FN9JCK/.4($0"NI#_4-))B4T'F>*YV>M:W/`\/(2BXF"#`0JH+"\0>HU]HG&(X(2T?!$)HK#&AL/#`\Q4X\8VC,EK#\J8:,1VQX5\2Z#:_S_6"TPPSM@9S+AED+1ZJ_X0UA8,^'$O$O/[PZDQ2M$*%R%+A`]LXQR8BM()HN6*=CZS(KA=0QDFS:@-1B)"/(@A/0*^8Y_\50=],EAG?["6YT['-+?.9KEZX@@ZVM!)UK#'3+-GE#`B*QQV-QTCMRV\!,G:5$FWV>BD?^)"X$3$W17$MN]O5A@9+#P7)31L`O9O5A:T-BD>NA`BUMW7+X6@06*^O:BZP=7TUY5'$$26"ITFN4TS4[M'3`0,^P38,8,`E/HHIS/_T;4A'#)>+F!ET(\K(2V@A4_Y%'1PP>M)M(G,#\.CXO)++\CL!+QJO`\2/@AS]ON3GSY*[4KKO6I_@07\@DGYU2F.>95MZ71RB,E!8(19!Y*D)IB3[-#>8@H+N7T3P*7/QK1735M12Y`SSEKWS4_^2,B'MC'`4C"[)"`QA`MU5W-K8P2?Z%%5"`72[6-"P3**YW"+#\629(@F_99MMYR42_B@]>_&2FV:*8W5X#V(F@^9YB(9'-XEE8B=[*W$9R#(QANJ1S;`4/E&_-M+ZI^S:A(TPC-PX;\&6+%M+[$BDX)RBM`+%Y@9/(&GK(2>-N/-9],%GNIW'O,N^=CC#AEV93Z6@@SDB6"!M_(H!^\22"U)9["8L9\B5H:W'4#!XI^E2ZM*M*QEY"-QSBC9.(Y;/I\C/SBVNY*!*;8JFXE(8_08OLK1QE\QV`IE!=)9IMX_P0Q*MD($J&E%3!+&?HL9FC0/V+6;C:-)#Q?G?23"5,?ZI276@>5`V>J6YC:"&)MUJM"F/I?Y$*"9)?(HTQS\,R8M`-9RQ,0!N:!3/Q]_]V5/M1&(E!47LKPM)GE*%M!3)A_OW4%BM9V$86T85;/70B:'2>NAC-5-R4$Y69-0'91I1>.,G;8CWAUD65B,#:H*P>M9PM8N-S=5G%99_6@JJC'+5A%\8%)>]G:W&Q,QDBB5]7*/,$>MVT_VMX0G(BYE`7M!PF,=H;X$`Z2AB>=0V>:^`[`-VDR"&?7AC5A18J&E#:=%FV&6!R-$RX]>'S^M5E8Q=78(`XK>)(^0F(2"%PO*&"\7$8YC1R=WP5/'@W%K`EY60S+Z@'`D07U^ME(`6\E?/,-(QF3V7-Z.2"`M*X$C>*F!S`6#VS@?^3..G?1V?40R9KJH6Q]5:MK0BDN9-$9G=9R1M>K*0AK[$&[\H)>FT4=$H:74X3^V$-JM9"(6Y-4&A36\R2$4:+T@*HQST@Z8)M@A3IBCRB)'9X#J!7G3?F70>BC04E#G-$9+:@%"4GMF)61@DL5(NM9Q"\*9N315/JN1^SI81/]FTVY8J!EX\&18ZZZB=CM!RGDZ@,1*U0%T9?'QXA'.&_'Y72^P*XKFPJ\^G0[+MF(#-AG#.-BI#RZ14NHV]%;#RJ+.NA29"ZUUB\WY?R"BN[]'.(=]9U>